Pasquale Iacopino

Dr. Pasquale Iacopino


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2012 in Cytometry Part A
Verified
Journal Article
Open access
PDF file
MLMarco F. Lombardo
Marco F. Lombardo
PIPasquale Iacopino
Pasquale Iacopino
MCMaria Cuzzola
Maria Cuzzola
ESElisa Spiniello
Elisa Spiniello
CGCristina Garreffa
Cristina Garreffa
GIGiuseppe Irrera
Giuseppe Irrera
Type 2 diabetes mellitus (T2DM) is associated with endothelial dysfunction, which leads to vascular complications. Endothelial progenitor cells (EPCs) are thought to be a subset of cells derived from the bone marrow that play a crucial role in the neovascularization of ischemic tissue and in the maintenance of endothelial cell integrity. In contrast, circulating endothelial cells (CECs) are of endothelial origin and become detached from the intima of blood vessels in response to pathological stimuli. The study investigated the effects of T2DM on subpopulations of EPCs and CECs in peripheral blood, as compared with the effects on unacylated (UAG) and acylated (AG) ghrelin levels, which have been shown recently to play an important role in endothelial dysfunction associated with diabetes. Using the high‐performance flow cytometer FACSCanto, and UAG/AG ghrelin enzyme immunoassay kits, we analyzed whole peripheral blood samples from: (i) diabetic patients with a history of disease of less than 1 year and no clinical evidence of angiopathy, (ii) diabetic patients with long‐standing disease with vascular complications, and (iii) healthy donors. We found that T2DM did not affect bone‐marrow mobilization, but it altered the UAG/AG profile and decreased the number of highly differentiated EPCs (late EPCs) greatly. In addition, T2DM increased the number of CECs, together with the number of activated CECs. Our results suggest that: (i) the endothelial damage could be due mainly to altered maturation/commitment of EPCs, rather than a simple decrease in their production in the bone marrow; and (ii) EPC subpopulations and ghrelin levels could be useful markers to assess endothelial damage in diabetes. © 2012 International Society for Advancement of Cytometry

17 September 2014 in Molecules
Verified
Journal Article
Open access
PDF file
GTGiacoma De Tullio
Giacoma De Tullio
VFVincenza De Fazio
Vincenza De Fazio
NSNicola Sgherza
Nicola Sgherza
carla minoiacarla minoia
carla minoia
Simona Serrati'Simona Serrati'
Simona Serrati'
AGAttilio Guarini
Attilio Guarini
MicroRNAs (miRNAs) are small non-coding RNAs that control the expression of many target messenger RNAs (mRNAs) involved in normal cell functions (differentiation, proliferation and apoptosis). Consequently their aberrant expression and/or functions are related to pathogenesis of many human diseases including cancers. Haematopoiesis is a highly regulated process controlled by a complex network of molecular mechanisms that simultaneously regulate commitment, differentiation, proliferation, and apoptosis of hematopoietic stem cells (HSC). Alterations on this network could affect the normal haematopoiesis, leading to the development of haematological malignancies such as lymphomas. The incidence of lymphomas is rising and a significant proportion of patients are refractory to standard therapies. Accurate diagnosis, prognosis and therapy still require additional markers to be used for diagnostic and prognostic purpose and evaluation of clinical outcome. The dysregulated expression or function of miRNAs in various types of lymphomas has been associated with lymphoma pathogenesis. Indeed, many recent findings suggest that almost all lymphomas seem to have a distinct and specific miRNA profile and some miRNAs are related to therapy resistance or have a distinct kinetics during therapy. MiRNAs are easily detectable in fresh or paraffin-embedded diagnostic tissue and serum where they are highly stable and quantifiable within the diagnostic laboratory at each consultation. Accordingly they could be specific biomarkers for lymphoma diagnosis, as well as useful for evaluating prognosis or disease response to the therapy, especially for evaluation of early relapse detection and for greatly assisting clinical decisions making. Here we summarize the current knowledge on the role of miRNAs in normal and aberrant lymphopoiesis in order to highlight their clinical value as specific diagnosis and prognosis markers of lymphoid malignancies or for prediction of therapy response. Finally, we discuss their controversial therapeutic role and future applications in therapy by modulating miRNA.

3 August 2006 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
Massimo MartinoMassimo Martino
Massimo Martino
GCGiuseppe Console
Giuseppe Console
GIGiuseppe Irrera
Giuseppe Irrera
GPGiulia Praticò
Giulia Praticò
CSCaterina Stelitano
Caterina Stelitano
PIPasquale Iacopino
Pasquale Iacopino

1 November 2002
Verified
Journal Article
Closed access
FMFortunato Morabito
Fortunato Morabito
Massimo MartinoMassimo Martino
Massimo Martino
CSCaterina Stelitano
Caterina Stelitano
EOEsther Oliva
Esther Oliva
MKMariagrazia Kropp
Mariagrazia Kropp
PIPasquale Iacopino
Pasquale Iacopino